Serum uric acid was reduced following treatment with empagliflozin at 4 weeks (vs. placebo: −1.12 ± 0.04 mg/dl, p < 0.0001) and remained lower throughout follow-up. treatment with empagliflozin reduced the risk of clinically relevant hyperuricemic events by 32% (hr 0.68 [95% ci 0.52-0.89], p = 0.004)..
